CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Migraine and associated symptoms
研究概览
简要总结
The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.
详细描述
Calcitonin gene-related peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in a large proportion of migraine sufferers. Treatment of spontaneous migraine attacks with an inhibitor of CGRP is effective in many patients. These data show that CGRP is involved in migraine pathophysiology.
The importance of migraine genetics is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of familial hemiplegic migraine (IHS-classification criteria)
- •Diagnosis of migraine with aura(IHS-classification criteria)
- •Healthy controls
排除标准
- •Patients and controls:
- •A history of cerebrovascular disease and other CNS- disease
- •A history of serious somatic and mental disease
- •A history suggesting ischaemic heart disease
- •A history of hypo- or hypertension
- •Daily intake of medication apart from oral contraceptives
- •Abuse of alcohol or medicine (opioid analgesics).
- •Pregnant or breastfeeding women.
- •On the study day:
- •No intake of a simple analgesic in the previous 48 hours
- •No headache in the previous 48 hours
研究组 & 干预措施
1
MA-patients
干预措施: CGRP (Drug)
2
FHM-patients
干预措施: CGRP (Drug)
3
Healthy controls
干预措施: CGRP (Drug)
结局指标
主要结局
Migraine and associated symptoms
时间窗: 0-14 h
次要结局
- Migraine aura(0 - 14 h)